Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma

Gameiro, Andreia; Urbano, Ana Catarina; Ferreira, Fernando

doi:10.3390/vetsci8080164

Cited by 10 publications

(9 citation statements)

References 161 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The non-luminal subtypes of FMC are made up of HER2-positive and triple-negative [ 8 , 37 ]. The HER2-positive subtype of FMC is designated by the overexpression of HER2 and lack of estrogen and progesterone receptors [ 8 , 36 ].…”

Section: Feline Mammary Cancermentioning

confidence: 99%

Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer

Marshall,

Chen,

Viloria-Petit

2023

Biomedicines

View full text Add to dashboard Cite

Obesity has been identified as a serious health concern in domestic cats. Feline mammary cancer (FMC) is also a concern, as it is highly prevalent and aggressive. Considering the identified connection between obesity and breast cancer, it is worthwhile to investigate the potential obesity–cancer relationship in FMC. This review investigated the association between adipokines and other obesity-associated molecules and FMC, with the aim of identifying gaps in the current literature for future research. Based on the reports to date, it was found that tissue concentrations of leptin, serum concentrations of leptin receptor, serum amyloid A, and estrogen correlate positively with FMC, and serum concentrations of leptin correlate negatively with FMC. The roles of adiponectin and prolactin in FMC development were also investigated, but the reports are either lacking or insufficient to suggest an association. Numerous research gaps were identified and could be used as opportunities for future research. These include the need for studies on additional cohorts to confirm the association of leptin/leptin receptor and serum amyloid A with FMC, and to address the role of adiponectin and prolactin in FMC. It is also important to investigate the genetic determinants of FMC, evaluate the use of molecular-targeted therapies in FMC, and exploit the enrichment of the triple-negative immunophenotype in FMC to address current clinical needs for both human triple-negative breast cancer and FMC. Finally, mechanistic studies with any of the molecules reviewed are scarce and are important to generate hypotheses and ultimately advance our knowledge and the outcome of FMC.

show abstract

Section: Feline Mammary Cancermentioning

confidence: 99%

Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer

Marshall,

Chen,

Viloria-Petit

2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…The same happens with the study of PV in cats and dogs, which can be extrapolated to studies of PV in humans, so it is necessary to study these two former species to benefit the three species. For example, it has been reported that Fc mammary carcinoma cancer may be useful as a model for human breast cancer because the markers and pathology are very similar to human breast cancer [ 64 , 65 , 66 ]. These similarities could occur with PV-associated cancers in humans, cats, and even dogs.…”

Section: Pv E5 Oncoprotein As a Biomarker Of Carcinogenesis In Hpv Cf...mentioning

confidence: 99%

Pathological Similarities in the Development of Papillomavirus-Associated Cancer in Humans, Dogs, and Cats

Cruz-Gregorio

Aranda-Rivera

Pedraza-Chaverri

2022

Animals

View full text Add to dashboard Cite

Canis familiaris, Felis catus, and human papillomavirus are nonenveloped viruses that share similarities in the initiation and development of cancer. For instance, the three species overexpress the oncoproteins E6 and E7, and Canis familiaris and human papillomavirus overexpress the E5 oncoprotein. These similarities in the pathophysiology of cancer among the three species are beneficial for treating cancer in dogs, cats, and humans. To our knowledge, this topic has not been reviewed so far. This review focuses on the information on cancer research in cats and dogs comparable to that being conducted in humans in the context of comparative pathology and biomarkers in canine, feline, and human cancer. We also focus on the possible benefit of treatment associated with the E5, E6, and E7 oncoproteins for cancer in dogs, cats, and humans.

show abstract

“…A deep understanding is needed to unveil therapeutic options aimed at improving the cat’s clinical outcome. Such studies are limited by a lack of feline cell lines available for cytotoxicity assays ( 22 ). Moreover, when comparing the two formulations of doxorubicin, the physical properties of the liposome play a major role in altering the drug’s pharmacokinetics, a factor intricately tied to both efficacy and adverse reactions ( 23 ).…”

Section: Introductionmentioning

confidence: 99%

Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration

Liu,

Chen,

Wen

et al. 2024

Front. Vet. Sci.

View full text Add to dashboard Cite

Doxorubicin, a potent chemotherapeutic agent used extensively in cancer treatment, displays complex pharmacokinetic behavior, especially across various formulations. With a rising incidence of cancer cases in cats, understanding the drug’s pharmacokinetics in feline subjects remains a critical yet unexplored area. Hence, this study investigated the pharmacokinetic profile of doxorubicin after slow intravenous administration of doxorubicin hydrochloride (DOX·HCl) or doxorubicin hydrochloride pegylated liposome (DOX·HCl-PLI) in twelve cats at a single dose of 20 mg/m2. Blood samples collected at pretreatment time (0 h) and over 192 h were analyzed using ultra-performance liquid chromatography-mass spectrometry (UPLC-MS/MS). The obtained pharmacokinetic parameters of doxorubicin revealed significant differences between the two formulations and were as follows: elimination half-life (T1/2λz) of 5.00 ± 3.20 h (DOX·HCl) and 17.62 ± 8.13 h (DOX·HCl-PLI), area under the concentration/time curve from 0 to last point (AUClast) of 0.67 ± 0.12 μg hr./mL (DOX·HCl) and 783.09 ± 267.29 μg hr./mL (DOX·HCl-PLI), and total body clearance (CL_obs) of 27098.58 ± 5205.19 mL/h/m2 (DOX·HCl) and 28.65 ± 11.09 mL/h/m2 (DOX·HCl-PLI). Additionally, differences were also detected in the apparent volume of distribution (Vz_obs) with 178.56 ± 71.89 L/m2 (DOX·HCl) and 0.64 ± 0.20 L/m2 (DOX·HCl-PLI), and the maximum plasma concentration (Cmax) with 2.25 ± 0.30 μg/mL (DOX·HCl) and 24.02 ± 5.45 μg/mL (DOX·HCl-PLI). Notably, low concentration of doxorubicinol, the metabolite of doxorubicin, was detected in plasma after administration of DOX·HCl, with even less present when DOX·HCl-PLI was administered. This investigation provides valuable insights into the distinct pharmacokinetic behaviors of DOX·HCl and DOX·HCl-PLI in cats, contributing essential groundwork for future studies and potential clinical applications in feline oncology.

show abstract

Emerging Biomarkers and Targeted Therapies in Feline Mammary Carcinoma

Cited by 10 publications

References 161 publications

Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer

Adipocyte-Derived Adipokines and Other Obesity-Associated Molecules in Feline Mammary Cancer

Pathological Similarities in the Development of Papillomavirus-Associated Cancer in Humans, Dogs, and Cats

Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration

Contact Info

Product

Resources

About